

List of Study Group 2021-2022

2022

1. Nakamae H, Yamamoto M, Sakaida E, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. *Int J Hematol.* 2022;115:33-42.
<https://link.springer.com/article/10.1007/s12185-021-03216-5>
2. Kitazawa J, Nakadate H, Matsubara K, Takahashi Y, Ishiguro A, Inoue E, et al. & Platelet Committee of the Japanese Society of Pediatric Hematology/Oncology. Favorable prognosis of vaccine-associated immune thrombocytopenia in children is correlated with young age at vaccination: Retrospective survey of nationwide disease registration. *Int J Hematol.* 2022;115:114-22.
<https://link.springer.com/article/10.1007/s12185-021-03230-7>
3. Hayakawa A, Sato I, Kamibeppu K, Ishida Y, Inoue M, Sato A, et al. Impact of chronic GVHD on QOL assessed by visual analogue scale in pediatric HSCT survivors and differences between raters: a cross-sectional observational study in Japan. *Int J Hematol.* 2022;115:123-8.
<https://link.springer.com/article/10.1007/s12185-021-03227-2>
4. Mori A, Onozawa M, Hidaka D, Yokoyama S, Miyajima T, Yokoyama E, et al. Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients. *Int J Hematol.* 2022;115:188-97.
<https://link.springer.com/article/10.1007/s12185-021-03238-z>

5. Hashimoto Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, et al. Clinical characteristics, prognostic factors, and outcomes of patients with essential thrombocythemia in Japan: the JSH-MPN-R18 study. *Int J Hematol.* 2022;115:208-21.
<https://link.springer.com/article/10.1007/s12185-021-03253-0>
6. Honda Y, Muramatsu H, Nanjo Y, Hirabayashi S, Meguro T, Yoshida N, et al. A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia. *Int J Hematol.* 2022;115:263-8.
<https://link.springer.com/article/10.1007/s12185-021-03248-x>
7. Kawaji-Kanayama Y, Muramatsu A, Sasaki N, Shimura K, Kiyota M, Fuchida S, et al. & Kyoto Clinical Hematology Study Group (KOTOSG) Investigators. Clinical impacts of frailty, poor performance status, and advanced age in carfilzomib-containing treatment for relapsed/refractory multiple myeloma: post hoc investigation of the KOTOSG multicenter pilot prospective observational study. *Int J Hematol.* 2022;115:350-62.
<https://link.springer.com/article/10.1007/s12185-021-03262-z>
8. Onishi C, Nishikori M, Yakushijin K, Kurahashi S, Nakazawa H, Takamatsu Y. Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. *Int J Hematol.* 2022;115:382-90.
<https://link.springer.com/article/10.1007/s12185-021-03281-w>
9. Nishikori M, Masaki Y, Fujii N, Ikeda T, Takahara-Matsubara M, Sugimoto S, et al. An expanded-access clinical study of thiotepa (DSP-1958) high-dose chemotherapy before autologous hematopoietic stem cell transplantation in patients with malignant lymphoma. *Int J Hematol.* 2022;115:391-8.
<https://link.springer.com/article/10.1007/s12185-021-03263-y>

10. Ikezoe T, Noji H, Ueda Y, Kanda Y, Okamoto S, Usuki K, et al. Long-term follow-up of patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab: post-marketing surveillance in Japan. *Int J Hematol.* 2022;115:470-80.
<https://link.springer.com/article/10.1007/s12185-022-03287-y>
11. Kitamura W, Fujii N, Nawa Y, Fujishita K, Sugiura H, Yoshioka T, et al. Possible prognostic impact of WT1 mRNA expression at day + 30 after haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for patients with myeloid neoplasm: a multicenter study from the Okayama Hematological Study Group. *Int J Hematol.* 2022;115:515-24.
<https://link.springer.com/article/10.1007/s12185-022-03290-3>
12. Onizuka M, Fujii N, Nakasone H, Ogata M, Atsuta Y, Suzuki R, et al. for the Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation. Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2022;115:534-44.
<https://link.springer.com/article/10.1007/s12185-021-03282-9>
13. Monsereenusorn C, Suwannaying K, Techavichit P, Sathitsamitphong L, Komvilaisak P, Rujkijyanont P, et al. Clinical outcomes and screening for organ involvement in pediatric Langerhans cell histiocytosis in Thailand: multicenter study on behalf of the Thai Pediatric Oncology Group. *Int J Hematol.* 2022;115:563-74.
<https://link.springer.com/article/10.1007/s12185-022-03293-0>
14. Shibata S, Takiuchi Y, Kawasaki N, Okamoto Y, Inano S, Fukunaga A, et al. NK-cell post-transplant lymphoproliferative disease successfully treated by second allogeneic hematopoietic stem cell transplantation in chronic active Epstein–Barr virus infection. *Int J Hematol.* 2022;115:595-9.
<https://link.springer.com/article/10.1007/s12185-021-03271-y>

15. Iida H, Imada K, Ueda Y, Kubo K, Yokota A, Ito Y, et al. & the Study Group. A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia. *Int J Hematol.* 2022;115:694-703.
<https://link.springer.com/article/10.1007/s12185-022-03307-x>
16. Hwang W-L, Chen T-C, Lin H-Y, Chang M-C, Hsiao P-C, Bai L-Y, et al. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. *Int J Hematol.* 2022;115:704-12.
<https://link.springer.com/article/10.1007/s12185-022-03311-1>
17. Fujiwara Y, Urata T, Niiya D, Yano T, Nawa Y, Yoshida I, et al. Higher incidence of thrombocytopenia during obinutuzumab plus bendamustine therapy for untreated follicular lymphoma: a retrospective analysis by the Okayama Hematology Study Group. *Int J Hematol.* 2022;115:811-5.
<https://link.springer.com/article/10.1007/s12185-022-03363-3>
18. Kawakami F, Kawakami T, Yamane T, Maruyama M, Kobayashi J, Nishina S, et al. T cell clonal expansion and *STAT3* mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia. *Int J Hematol.* 2022;115:816-25.
<https://link.springer.com/article/10.1007/s12185-022-03310-2>
19. Tsumanuma R, Omoto E, Kumagai H, Katayama Y, Iwato K, Aoki G, et al. The safety and efficacy of hematopoietic stem cell mobilization using biosimilar filgrastim in related donors. *Int J Hematol.* 2022;115:882-9.
<https://link.springer.com/article/10.1007/s12185-022-03318-8>

20. Takahashi Y, Ishida H, Imamura T, Tamefusa K, Suenobu S, Usami I, et al. JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia. *Int J Hematol.* 2022;115:890-7.
<https://link.springer.com/article/10.1007/s12185-022-03315-x>
21. Yoshida C, Kondo T, Ito T, Kizaki M, Yamamoto K, Miyamoto T, et al. Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy. *Int J Hematol.* 2022;116:89-101.
<https://link.springer.com/article/10.1007/s12185-022-03334-8>
22. Kim K, Kim JS, Yoon S-S, Yoon DH, Eom H-S, Lee JJ, et al. & The Korean Multiple Myeloma Working Party (KMMWP). Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). *Int J Hematol.* 2022;116:110-21.
<https://link.springer.com/article/10.1007/s12185-022-03332-w>
23. Matsue K, Sunami K, Matsumoto M, Kuroda J, Sugiura I, Iwasaki H, et al. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. *Int J Hematol.* 2022;116:122-30.
<https://link.springer.com/article/10.1007/s12185-022-03338-4>
24. Kodama Y, Sato A, Kato K, Sakaguchi H, Kato M, Kawasaki H, et al. Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group. *Int J Hematol.* 2022;116:131-8.
<https://link.springer.com/article/10.1007/s12185-022-03329-5>

25. Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y et al. On behalf of Japan Adult Leukemia Study Group. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. *Int J Hematol.* 2022;116:228–38.
<https://link.springer.com/article/10.1007/s12185-022-03347-3>
26. Teramoto M, Maruyama S, Tamaki H, Kaida K, Mayumi A, Fukunaga K, et al. Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation. *Int J Hematol.* 2022;116:248–57.
<https://link.springer.com/article/10.1007/s12185-022-03342-8>
27. Cioce M, Botti S, Lohmeyer FM, Galli E, Magini M, Giraldi A, et al. Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2022;116:266–75.
<https://link.springer.com/article/10.1007/s12185-022-03351-7>
28. Nishiyama A, Ogiwara K, Nakajima Y, Furukawa S, Matsumoto T, Takeda H, et al. A case of a young boy with hyperfibrinolysis associated with natural fibrin precipitates suspected to have occurred through a novel coagulation and fibrinolysis mechanism. *Int J Hematol.* 2022;116:276-87.
<https://link.springer.com/article/10.1007/s12185-022-03339-3>
29. Arai Y, Chi SG, Minami Y, Yanada M. FLT3-targeted treatment for acute myeloid leukemia. *Int J Hematol.* 2022;116:351–63.
<https://link.springer.com/article/10.1007/s12185-022-03374-0>

30. Kobayashi T, Sugiura K, Ojima T, Hirai K, Morishita E. Peripartum management of hereditary thrombophilia: results of primary surveillance in Japan. *Int J Hematol.* 2022;116:364–71.
<https://link.springer.com/article/10.1007/s12185-022-03354-4>
31. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, et al. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia *Int J Hematol.* 2022;116:393–400.
<https://link.springer.com/article/10.1007/s12185-022-03368-y>
32. Iida S, Ishida T, Miyamoto T, Teramukai S, Shirai H, Kanamori R, et al. MEDICAL Database AnaLysis of Japanese multiple myeloma patients with apheresis #2 (MEDALIST-2): the impact of plerixafor use on costs and healthcare resources during mobilization and stem cell transplantation. *Int J Hematol.* 2022;116:411–22.
<https://link.springer.com/article/10.1007/s12185-022-03356-2>
33. Ono R, Sakamoto K, Doi T, Yanagisawa R, Tamura A, Hashimoto H, et al. on behalf of The HLH/LCH committee members of the Japan Children's Cancer Group. A retrospective survey of patients who discontinued participation in the JPLSG HLH-2004 clinical trial. *Int J Hematol.* 2022;116:434–41.
<https://link.springer.com/article/10.1007/s12185-022-03357-1>
34. Uchino K, Kanasugi J, Enomoto M, Kitamura F, Tsuchida N, Uchiyama Y, et al. VEXAS syndrome. *Int J Hematol.* 2022;116:463–4.
<https://link.springer.com/article/10.1007/s12185-022-03448-z>

35. Kim K, Min C-K, Koh Y, Ishizawa K, Kim S-H, Ito S, et al. Isatuximab plus carfilzomib and dexamethasone in East Asian patients with relapsed multiple myeloma: IKEMA subgroup analysis. *Int J Hematol.* 2022;116: 553–62.
<https://link.springer.com/article/10.1007/s12185-022-03378-w>
36. Murakami S, Ri M, Ito M, Nakamura N, Kasahara S, Kitagawa J, et al. Efficacy and safety of modified BLD therapy for Japanese patients with transplant-ineligible multiple myeloma. *Int J Hematol.* 2022;116:563–9.
<https://link.springer.com/article/10.1007/s12185-022-03379-9>
37. Tachibana T, Tanaka M, Hagihara M, Fujimaki K, Kanamori H, Nakajima H. Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation *Int J Hematol.* 2022;116:594–602.
<https://link.springer.com/article/10.1007/s12185-022-03377-x>
38. Nakayama H, Ogawa C, Sekimizu M, Fujisaki H, Kosaka Y, Hashimoto H, et al. A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1). *Int J Hematol.* 2022;116:612–21.
<https://link.springer.com/article/10.1007/s12185-022-03388-8>
39. Kawabata H, Tamura T, Tamai S, Fujibayashi A, Sugimura M & Study Group. Intravenous ferric derisomaltose versus saccharated ferric oxide for iron deficiency anemia associated with menorrhagia: a randomized, open-label, active-controlled, noninferiority study. *Int J Hematol.* 2022;116:647–58.
<https://link.springer.com/article/10.1007/s12185-022-03401-0>

40. Edahiro Y, Ito T, Gotoh A, Nakamae M, Kimura F, Koike M, et al. Clinical characteristics of Japanese patients with polycythemia vera: results of the JSH-MPN-R18 study. *Int J Hematol.* 2022;116:696–711.
<https://link.springer.com/article/10.1007/s12185-022-03412-x>
41. Harada K, Najima Y, Kato M, Fuji S, Shinohara A, Nakamae H, et al. Outcomes of salvage haploidentical transplantation using posttransplant cyclophosphamide for graft failure following allogeneic hematopoietic stem cell transplantation. *Int J Hematol.* 2022;116:744–53.
<https://link.springer.com/article/10.1007/s12185-022-03405-w>
42. Nagamura-Inoue T, Kato S, Najima Y, Isobe M, Doki N, Yamamoto H, et al. Immunological influence of serum-free manufactured umbilical cord-derived mesenchymal stromal cells for steroid-resistant acute graft-versus-host disease. *Int J Hematol.* 2022;116:754–69.
<https://link.springer.com/article/10.1007/s12185-022-03408-7>
43. Liu MA, Lee C-C, Phung Q, Dao Q-L, Tehrani B, Yao M, et al. Incidence and predictors of idiopathic pneumonia syndrome in hematopoietic stem cell transplant patients: a nationwide registry study. *Int J Hematol.* 2022;116:770–7.
<https://link.springer.com/article/10.1007/s12185-022-03417-6>
44. Ishida Y, Kamibeppu K, Sato A, Inoue M, Hayakawa A, Shiobara M, et al. Karnofsky performance status and visual analogue scale scores are simple indicators for quality of life in long-term AYA survivors who received allogeneic hematopoietic stem cells transplantation in childhood. *Int J Hematol.* 2022;116:787–97.
<https://link.springer.com/article/10.1007/s12185-022-03426-5>

45. Kawabata H, Tamura T, Tamai S, Takahashi T, Kato J & Study Group. Intravenous ferric derisomaltose for iron-deficiency anemia associated with gastrointestinal diseases: a single-arm, randomized, uncontrolled, open-label study. *Int J Hematol.* 2022;116:846–55.
<https://link.springer.com/article/10.1007/s12185-022-03420-x>
46. Ono T, Hino M, Matsumura I, Fujisawa S, Ishizawa K, Sakaida E, et al. Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study. *Int J Hematol.* 2022;116:871–82.
<https://link.springer.com/article/10.1007/s12185-022-03435-4>
47. Aydin S, Passera R, Scaldaferrri M, Dellacasa CM, Poggiu M, Cattel F, et al. Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia. *Int J Hematol.* 2022;116:883–91.
<https://link.springer.com/article/10.1007/s12185-022-03427-4>
48. Goto H, Izutsu K, Ennishi D, Mishima Y, Makita S, Kato K, et al. Zandelisib (ME-401) in Japanese patients with relapsed or refractory indolent non-Hodgkin's lymphoma: an open-label, multicenter, dose-escalation phase 1 study. *Int J Hematol.* 2022;116:911–21.
<https://link.springer.com/article/10.1007/s12185-022-03450-5>

2021

1. Fujimoto S, Kawabata H, Sakai T, Yanagisawa H, Nishikori M, Nara K, et al. Optimal treatments for TAFRO syndrome: a retrospective surveillance study in Japan. *Int J Hematol.* 2021;113:73-80.
<https://link.springer.com/article/10.1007/s12185-020-03008-3>
2. Lee HS, Kim K, Lee J-J, Yoon S-S, Bang S-M, Kim JS, et al. & The Korean Multiple Myeloma Working Party (KMMWP). Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. *Int J Hematol.* 2021;113:81-91.
<https://link.springer.com/article/10.1007/s12185-020-02988-6>
3. Edahiro Y, Yasuda H, Gotoh A, Morishita S, Suzuki T, Takeda J, et al. Interferon therapy for pregnant patients with essential thrombocythemia in Japan. *Int J Hematol.* 2021;113:106-11.
<https://link.springer.com/article/10.1007/s12185-020-03001-w>
4. Kikuchi T, Mori T, Ohwada C, Onoda M, Shimizu H, Yokoyama H, et al. & Kanto Study Group for Cell Therapy (KSGCT). Pharmacokinetics of intravenous busulfan as condition for hematopoietic stem cell transplantation: comparison between combinations with cyclophosphamide and fludarabine. *Int J Hematol.* 2021;113:128-33.
<https://link.springer.com/article/10.1007/s12185-020-02990-y>
5. Yabe M, Morio T, Tabuchi K, Tomizawa D, Hasegawa D, Ishida H, et al. Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis. *Int J Hematol.* 2021;113:134-44.
<https://link.springer.com/article/10.1007/s12185-020-02991-x>

6. Iida S, Ishida T, Horimoto K, Kazama H, Kim H, Crawford B, et al. Medical database analysis of Japanese multiple myeloma patients with planned stem cell transplantation (MEDALIST) – a focus on healthcare resource utilization and cost. *Int J Hematol.* 2021;113:271-8.
<https://link.springer.com/article/10.1007/s12185-020-03022-5>
 7. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, et al. & Japan Adult Leukemia Study Group. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. *Int J Hematol.* 2021;113:395-403.
<https://link.springer.com/article/10.1007/s12185-020-03032-3>
 8. Ieko M, Hotta T, Watanabe K, Adachi T, Takeuchi S, Naito S, et al. Comparative evaluation of reagents for measuring protein S activity: possibility of harmonization. *Int J Hematol.* 2021;113:530-6.
<https://link.springer.com/article/10.1007/s12185-020-03049-8>
 9. Soejima T, Shiohara M, Ishida Y, Inoue M, Hayakawa A, Sato A, et al. Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. *Int J Hematol.* 2021;113:566-75.
<https://link.springer.com/article/10.1007/s12185-020-03058-7>
- Correction to: Impact of cGVHD on socioeconomic outcomes in survivors with pediatric hematopoietic stem cell transplant in Japan: a cross-sectional observational study. *Int J Hematol.* 2021;113:466-9.
<https://link.springer.com/article/10.1007/s12185-021-03090-1>

10. Morishige S, Miyamoto T, Eto T, Uchida N, Kamimura T, Miyazaki Y, et al. Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008. *Int J Hematol.* 2021;113:815-22.
<https://link.springer.com/article/10.1007/s12185-021-03116-8>
11. Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, et al. Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. *Int J Hematol.* 2021;113: 840-50.
<https://link.springer.com/article/10.1007/s12185-021-03097-8>
12. Ishida H, Yano M, Hasegawa D, Hori T, Hashii Y, Kato K, et al. Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study. *Int J Hematol.* 2021;113:893-902.
<https://link.springer.com/article/10.1007/s12185-021-03110-0>
13. Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, et al. Expression of activated integrin $\beta 7$ in multiple myeloma patients. *Int J Hematol.* 2021;114:3-7.
<https://link.springer.com/article/10.1007/s12185-021-03162-2>
14. Tanaka C, Tagami T, Kudo S, Takehara A, Fukuda R, Nakayama F, et al. Validation of sepsis-induced coagulopathy score in critically ill patients with septic shock: post hoc analysis of a nationwide multicenter observational study in Japan. *Int J Hematol.* 2021;114:164-71.
<https://link.springer.com/article/10.1007/s12185-021-03152-4>

15. Konishi T, Sekiya N, Otsuka Y, Konuma R, Wada A, Adachi H, et al. Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. *Int J Hematol.* 2021;114:263-70.
<https://link.springer.com/article/10.1007/s12185-021-03146-2>
16. Arakawa Y, Masutani S, Oshima K, Mitani Y, Mori M, Fukuoka K, et al. Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia. *Int J Hematol.* 2021;114:271-9.
<https://link.springer.com/article/10.1007/s12185-021-03163-1>
17. Lee Y-P, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen T-Y, et al. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. *Int J Hematol.* 2021;114:355-62.
<https://link.springer.com/article/10.1007/s12185-021-03179-7>
18. Okamoto A, Kanda Y, Kimura S, Oyake T, Tamura K & from the Japan Febrile Neutropenia Study Group. Predictive and risk factor analysis for bloodstream infection in high-risk hematological patients with febrile neutropenia: post-hoc analysis from a prospective, large-scale clinical study. *Int J Hematol.* 2021;114:472-82.
<https://link.springer.com/article/10.1007/s12185-021-03183-x>
19. Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, et al. Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy. *Int J Hematol.* 2021;114:608-19.
<https://link.springer.com/article/10.1007/s12185-021-03198-4>